Solutions

Healthcare-Associated Infections Portfolio

A comprehensive suite of solutions for the screening & active infection management of HAIs and MDROs

The BD MAX™ Portfolio of HAI assays Setting higher standards in the fight against HAIs

The efficiency and versatility offered by the BD MAX™ System and the Healthcare-Associated Infections (HAIs) portfolio provides a comprehensive suite of solutions on a single, fully automated platform, enabling the laboratory to provide rapid, accurate results which can positively impact patient management.

Burden of HAIs

Consequences of HAIs

HAI detection and infection control

Burden of HAIs

  • 4 million patients in Europe per year
    acquire an HAI1,     at a cost of an estimated €7
    billion to healthcare providers.2
  • Compounding the impact of HAIs are
    infections due to bacteria resistant to
    antimicrobials (AMR)    , many resistant to
    multiple antimicrobials (MDROs). Therefore,
    AMR is a major concern in relation to HAIs.

Consequences of HAIs

Each year, hundreds of millions of patients worldwide are affected by HAIs, or infections acquired in healthcare settings, leading to2,3

  • Significant mortality
  • Human and economic burden
  • Prolonged hospital stays
  • Long-term disability
  • Increased antimicrobial resistance

HAI detection and infection control

Early and accurate detection of HAIs combined with appropriate infection control interventions and patient treatment can:

  • Support antimicrobial stewardship initiatives
  • Prevent transmission
  • Improve patient satisfaction and life planning
  • Improve patient management

Meet the BD MAX™ Enteric Suite assays

More timely and accurate results enable:

  • Optimal patient management and faster results reporting to inform clinical decisions
  • Improved clinical interventions, i.e. optimal antimicrobial usage and ability to bring in infection control measures earlier to prevent infection spread

BD’s focused syndromic approach provides the flexibility to optimize testing algorithms by selecting the most appropriate enteric panel(s) based on patient history/clinical presentation.

BD MAX™
Enteric Bacterial Panel
  • Salmonella spp.
  • Campylobacter spp. (C. jejuni and C. coli)
  • Shigella spp. (including EIEC)
  • Shiga toxin 1/Shiga toxin 2 genes (found in STEC)
BD MAX™
Extended Enteric Bacterial Panel
  • Plesiomonas shigelloides
  • Vibrio spp. (V. vulnuficus, V. parahaemo lyticus, V. cholerae)
  • Enterotoxigenic E. coli (ETEC)
  • Yersinia entercolitica
BD MAX™
Enteric Parasite Panel
  • Giardia lamblia
  • Cryptosporidium (C. hominis and C. parvum)
  • Entamoeba histolytica
BD MAX™
Enteric Viral Panel
  • Norovirus GI & GII
  • Rotavirus A
  • Adenovirus F40/41
  • Sapovirus (genogroups I, II, IV, V)
  • Human Astrovirus (hAstro)
BD MAX™
Enteric Viral Panel-NR
  • Norovirus GI & GII
  • Rotavirus A

EIEC, Enteroinvasive Escherichia coli; ETEC, Enterotoxigenic Escherichia coli; hAstro, Human Astrovirus; STEC, Shiga toxin–producing Escherichia coli.

Shigella dysenteriae can possess a Shiga toxin gene identical to the Shiga toxin 1 found in STEC.

1. World Health Organization. Diarrhoeal disease. Available at: https://www.who.int/news-room/fact-sheets/detail/diarrhoeal-disease. Accessed May 2020. 2. Bartsch et al. PLoS ONE. 2016;11(4):e0151219. 3. Mortensen et al. BMC Clin Pathol. 2015;15:9. 4. Anderson et al. J Clin Microbiol. 2014;52(4):1222-1224. 5. Centers for Disease Control and Prevention. Parasites – Amebiasis – Entamoeba histolytica Infection. Available at: https://www.cdc.gov/parasites/amebiasis/index.html. Updated December 16, 2015. Accessed May 2020. 6. Humphries R et al. Clin Microbiol Rev. 2015;28(1):3-31.

Meet the BD MAX™ Portfolio of HAI assays

The BD MAX™ Portfolio of HAI assays enables your laboratory to:

  • Provide results for up to 24 specimens in less than 3 hours
  • Decrease hands-on time for laboratory technicians versus traditional methods
  • Limit the risk of potential errors and maintain chain of custody including sample transfers and manual manipulations
  • Control total cost of ownership by limiting indirect costs

Detection of Gram Negative pathogens

BD MAX™
Check-Points CPO assay
Screening for carbapenemase-producing organism (CPO) through the identification of the five most common carbapenemase genes:
  • KPC
  • OXA-48 (OXA-48 and OXA-48 like)
  • NDM
  • VIM/IMP
Check-Points [Check-Direct]
ESBL Screen for BD MAX™4
Screening for extended-spectrum beta-lactamase (ESBL) producing pathogenic enterobacteria, can be run in parallel with BD MAX™ Check-Points CPO to detect ESBLs and carbapenemases simultaneously:
  • CTX-M-1 group
  • CTX-M-2 group
  • CTX-M-9 group
  • SHV-ESBL

Detection of Gram Positive pathogens

BD MAX™
MRSA XT
Active surveillance of methicillin- resistant Staphylococcus aureus (MRSA) with Extended Detection Technology including mecA and mecC resistance
BD MAX™
StaphSR
Differentiation of S. aureus and MRSA with the same Extended Detection Technology as the BD MAX™ MRSA XT assay
BD MAX™
Cdiff
Detection of toxigenic Clostridioides difficile through the identification of toxin B gene (tcdB)
VIASURE VanR Real
Time PCR Detection
Kit for BD MAX™
Active surveillance of vancomycin-resistant enterococci through the detection of vanA and vanB genes

The BD MAX™ System is a single platform
providing you with the versatility of running BD and partner developed assays,
as well as 3rd party and laboratory developed tests.

CPO, Carbapenemase-Producing Organism; CTX, cefotaxime-beta lactamases; ESBL, Extended-Spectrum Beta-Lactamase; HAI, Healthcare-Associated Infections; IMP, imipenemase; KPC, Klebsiella pneumoniae carbapenemase; MDRO, Multidrug-Resistant Organism; MRSA, Methicillin-Resistant Staphylococcus aureus; NDM, New Delhi metallo-β-lactamase; OXA, oxacillinase; SHV, sulphydryl variable; tcdB, toxin B gene; VIM, Verona integron-encoded metallo-β-lactamase

1. European Centre for Disease Prevention and Control. ECDC Programme on antimicrobial resistance and healthcare-associated infections. Available at: https://wiki.ecdc.europa.eu/fem/Pages/ECDC%20Programme%20on%20antimicrobial%20resistance%20and%20healthcare-associated%20infections.aspx. Accessed February 2021. 2. World Health Organization. Health care-associated infections fact sheet. Available at: https://www.who.int/gpsc/country_work/gpsc_ccisc_fact_sheet_en.pdf. Accessed February 2020. 3. World Health Organization. 2016. Health care without avoidable infections. Available at: https://apps.who.int/iris/bitstream/handle/10665/246235/WHO-HIS-SDS-2016.10-eng.pdf;jsessionid=C477D74DC9AF05C3BEA0474CF2C8B601?sequence=1. Accessed February 2020. 4. Check-Direct ESBL for BD MAX Distributed by Check-Points, [email protected].

Contact us

to discuss how we can support your HAI screening needs